1. Scrip
  2. >>Business

Motif A Step Closer To Succeeding With Iclaprim After Phase III Success

 
• By Joseph Haas

Biotech firm hopes its once-shelved antibiotic will provide a therapeutic option for renally impaired patients with serious skin infections. With only one previous DHFR inhibitor ever approved, Motif also anticipates that iclaprim will offer an option for multidrug-resistant infections.

Antibiotic resistant bacteria closeup biofilm

Motif Bio PLC unveiled positive top-line Phase III data for novel antibiotic iclaprim in acute bacterial skin and skin structure infections (ABSSSI) April 18, which moves the drug one step closer to US and EU approval after it was shipwrecked by safety concerns around antibiotics nearly one decade ago.

The clinical-stage firm, based both in New York and London, announced that the synthetic diaminopyrimidine demonstrated non-inferiority to vancomycin across several measures in 600 patients hospitalized for ABSSSI

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.